HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aesthetic Medicine

625.159

+9.2491.50%

Number of Gainers:5

Number of Losers:6

Number of Flat:2

PE:- -

High:633.963

Open:614.939

Low:614.113

Close:615.910

Loading ...

Raily Aesthetic Medicine International Sees FY Loss Attributable of RMB59 Mln

THOMSON REUTERS

BRIEF-Raily Aesthetic Medicine International Says Unit To Buy Property In Jiangsu Province For RMB21.4 Mln

Raily Aesthetic Medicine International - Unit to Acquire Property in Jiangsu Province for RMB21.4 Mln

THOMSON REUTERS

Fosun Pharma Unit Gets China Nod to Register Foritinib Succinate Capsules

MT Newswires Live

Chinese Regulator Approves Shanghai Fosun Pharmaceutical's Vaccine for Clinical Trials

MT Newswires Live

EC Healthcare Completes Major Stake Disposal, Acquisition

MT Newswires Live

Miricor Enterprises - Unit Entered Facility Agreement With Bank for Trade Finance & Revolving Loan Facility up to HK$10 Mln

THOMSON REUTERS

Fosun Pharmaceutical Secures Clinical Trial Approval for Colorectal Cancer Treatment

MT Newswires Live

Fosun Pharmaceutical Gets Marketing Authorization for Chronic Kidney Disease Drug

MT Newswires Live

Fosun Pharmaceutical Unit Gets Chinese Regulator's Nod for Chronic Kidney Disease Tablets

MT Newswires Live

Fosun Pharmaceutical Unit Gets China Nod for Lung Diseases Drug

MT Newswires Live

Fosun Pharmaceutical Unit Gets China Nod for Colon Cleansing Granules

MT Newswires Live

BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate Granules

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK1593/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1593"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":625.15894,"timestamp":1741594084363,"preClose":615.91016,"halted":0,"volume":102329963,"delay":0,"changeRate":0.015016,"change":9.248779,"pbRate":1.190795,"amount":775101220,"amplitude":0.03223,"prevYearClose":571.87146,"fiveDayClose":604.125,"twentyDayClose":578.349,"turnoverRate":0.005049,"marketCap":112033200160,"floatMarketCap":74569710368,"peRate":21.56404},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":633.96344,"amplitude":0.03223,"preClose":615.91016,"low":614.11285,"pbRate":"1.190795","latestPrice":625.15894,"volume":102329963,"delay":0,"open":614.9391,"prevYearClose":571.87146,"prevWeekClose":615.91,"prevMonthClose":612.07,"prevQuarterClose":571.871,"fiveDayClose":604.125,"twentyDayClose":578.349,"sixtyDayClose":582.226,"secType":"PLATE","market":"HK","turnoverRate":0.005049,"peRate":21.56404,"marketCap":112033200160,"floatMarketCap":74569710368,"timestamp":1741594084363,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":5,"down":6,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518275815","title":"Raily Aesthetic Medicine International Sees FY Loss Attributable of RMB59 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2518275815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518275815?lang=en_us&edition=fundamental","pubTime":"2025-03-10 22:37","pubTimestamp":1741617473,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nPLX628823:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","BK1209","02135"],"gpt_icon":0},{"id":"2517107575","title":"BRIEF-Raily Aesthetic Medicine International Says Unit To Buy Property In Jiangsu Province For RMB21.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2517107575","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517107575?lang=en_us&edition=fundamental","pubTime":"2025-03-07 18:21","pubTimestamp":1741342875,"startTime":"0","endTime":"0","summary":"BRIEF-Raily Aesthetic Medicine International Says Unit To Buy Property In Jiangsu Province For RMB21.4 MlnMarch 7  - Raily Aesthetic Medicine International Holdings Ltd 2135.HK:UNIT TO ACQUIRE PROPERTY IN JIANGSU PROVINCE FOR RMB21.4 MILLIONFurther company coverage: 2135.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0EN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02135","BK1593","BK1209"],"gpt_icon":0},{"id":"2517107833","title":"Raily Aesthetic Medicine International - Unit to Acquire Property in Jiangsu Province for RMB21.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2517107833","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517107833?lang=en_us&edition=fundamental","pubTime":"2025-03-07 18:15","pubTimestamp":1741342500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0EN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1209","BK1593","02135"],"gpt_icon":0},{"id":"2517126956","title":"Fosun Pharma Unit Gets China Nod to Register Foritinib Succinate Capsules","url":"https://stock-news.laohu8.com/highlight/detail?id=2517126956","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517126956?lang=en_us&edition=fundamental","pubTime":"2025-03-07 12:42","pubTimestamp":1741322561,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  unit, Fosun Wanbang  Pharmaceutical Group, has secured approval from China's National Medical Products Administration to register its foritinib succinate capsules, according to a Hong Kong stock exchange filing on Thursday.The drug is primarily used to treat non-small cell lung cancer patients that are anaplastic lymphoma kinase-positive and those with non-small cell lung cancer , the pharmaceutical company said.Shares of Fosun Pharma rose over 2% in Hong Kong and nearly 1% in Shanghai in recent trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0060","BK1191","00656","BK0012","02196","BK0175","BK0096","BK0187","600196","BK0188","BK0183","BK1593","BK0196","BK1515","BK1230","BK0239"],"gpt_icon":0},{"id":"2516768536","title":"Chinese Regulator Approves Shanghai Fosun Pharmaceutical's Vaccine for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2516768536","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516768536?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:07","pubTimestamp":1741093665,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's   subsidiary Fosun Adgenvax  Biopharmaceutical obtained the National Medical Products Administration's approval for clinical trials for its 24-valent pneumococcal polysaccharide conjugate vaccine, a Tuesday bourse filing said.Fosun Adgenvax  Biopharmaceutical plans to start the first phase of clinical trials in China.The vaccine is a preventive biological product used for the prevention of certain infectious diseases caused by certain pneumococcal serotypes.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0060","BK1191","00656","BK0012","02196","BK0175","BK0096","BK0187","600196","BK0188","BK0183","BK0196","BK1515","BK1593","BK0239"],"gpt_icon":0},{"id":"2516508022","title":"EC Healthcare Completes Major Stake Disposal, Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2516508022","media":"MT Newswires Live","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516508022?lang=en_us&edition=fundamental","pubTime":"2025-03-03 15:06","pubTimestamp":1740985570,"startTime":"0","endTime":"0","summary":"EC Healthcare's  subsidiary, Jade Master International, completed the sale of its 51% stake in New Medical Centre to AIA Hong Kong Medical Services on Friday, a Monday Hong Kong bourse filing said.The transaction was first announced in November 2024, with Jade Master agreeing to dispose of the majority stake for HK$437.6 million.The company also completed the acquisition of a 40% stake in its unit, Hong Kong Medical Advanced Imaging , as part of an internal reorganization within the group.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","HCSG","TST","BK1215","02138","EC","BK1511","SES.SI","BK4137","BK4201"],"gpt_icon":0},{"id":"2514103713","title":"Miricor Enterprises - Unit Entered Facility Agreement With Bank for Trade Finance & Revolving Loan Facility up to HK$10 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514103713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514103713?lang=en_us&edition=fundamental","pubTime":"2025-02-28 16:49","pubTimestamp":1740732577,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ0MQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","01827","BK1215"],"gpt_icon":0},{"id":"2514393555","title":"Fosun Pharmaceutical Secures Clinical Trial Approval for Colorectal Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2514393555","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514393555?lang=en_us&edition=fundamental","pubTime":"2025-02-28 12:07","pubTimestamp":1740715674,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Xingsheng Xinhui Pharmaceutical received approval from China's medical products administrator to conduct clinical trials for a colorectal cancer drug.Specifically, the approval was for trials using XS-03 tablets in combination with FOLFOX or FOLFIRI and bevacizumab for the treating RAS-mutated metastatic colorectal cancer, according to a Thursday filing with the Shanghai bourse.Xingsheng Xinhui plans to initiate Phase Ib/II clinical trials for this treatment regimen in mainland China once conditions are met.Shares of the pharmaceutical company were down 1% in recent trade on the Shanghai bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0239","BK0028","600196","00656","02196","BK0188","BK1515","BK0187","BK0060","BK0096","BK1230","BK1191","BK0183","BK0196","BK1593","BK0012"],"gpt_icon":0},{"id":"2514434848","title":"Fosun Pharmaceutical Gets Marketing Authorization for Chronic Kidney Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2514434848","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514434848?lang=en_us&edition=fundamental","pubTime":"2025-02-27 11:58","pubTimestamp":1740628689,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  obtained marketing authorization for tenapanol hydrochloride tablets from China's food and drug administrator.The drug is used to control serum phosphorus levels in adult dialysis patients with chronic kidney disease who have inadequate response or intolerance to phosphate binders, according to a Thursday filing with the Shanghai bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","BK0175","BK0096","BK1515","BK1593","00656","BK0196","BK0060","BK0012","02196","BK0028","BK0183","BK0187","BK1191","BK0239","600196"],"gpt_icon":0},{"id":"2514319348","title":"Fosun Pharmaceutical Unit Gets Chinese Regulator's Nod for Chronic Kidney Disease Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2514319348","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514319348?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:21","pubTimestamp":1740572493,"startTime":"0","endTime":"0","summary":"China approved Shanghai Fosun Pharmaceutical  subsidiary Shanghai Fosun Pharmaceutical Industrial Development's tenapanor hydrochloride tablets for an indication of chronic kidney disease, according to a Wednesday filing with the Hong Kong Exchange.The tablets help control serum phosphorus levels in dialysis patients with chronic kidney disease who do not have an adequate response to phosphorus binders, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK0188","BK0187","BK1515","BK0028","BK0239","600196","00656","BK0196","BK1593","BK0060","BK0175","BK0183","BK0096","BK0012","02196"],"gpt_icon":0},{"id":"2514675831","title":"Fosun Pharmaceutical Unit Gets China Nod for Lung Diseases Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2514675831","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514675831?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:18","pubTimestamp":1740572317,"startTime":"0","endTime":"0","summary":"China accepted Shanghai Fosun Pharmaceutical  subsidiary Yaopharma's drug registration application for its bromhexine hydrochloride injection, according to a Wednesday filing with the Hong Kong Exchange.The drug is an expectorant indicated for lung ailments such as pulmonary tuberculosis, pneumoconiosis, or postoperative sputum retention, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0183","BK0187","BK1593","02196","BK0060","600196","BK1191","BK0239","BK0175","BK1515","BK0188","BK0096","00656","BK0012","BK0196"],"gpt_icon":0},{"id":"2514315528","title":"Fosun Pharmaceutical Unit Gets China Nod for Colon Cleansing Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=2514315528","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514315528?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:17","pubTimestamp":1740572245,"startTime":"0","endTime":"0","summary":"China granted Shanghai Fosun Pharmaceutical  subsidiary Suzhou Erye Pharmaceutical marketing approval for its compound sodium picosulfate granules for colon cleansing.The drug contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, and is used to clean the colon for colonoscopy or X-rays, and for preparation for colon surgery, according to a Wednesday filing with the Hong Kong Exchange.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","BK0196","02196","00656","BK1515","600196","BK0188","BK0012","BK0239","BK0060","BK0187","BK0175","BK0028","BK0096","BK1191","BK0183"],"gpt_icon":0},{"id":"2514898880","title":"BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898880","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898880?lang=en_us&edition=fundamental","pubTime":"2025-02-26 18:31","pubTimestamp":1740565889,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma's Unit Received Marketing Registration Approval From NMPA China For Compound Sodium Picosulfate GranulesFeb 26  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:UNIT RECEIVED MARKETING REGISTRATION APPROVAL FROM NMPA CHINA FOR COMPOUND SODIUM PICOSULFATE GRANULESFurther company coverage: 600196.SS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH0XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK1191","BK1515","BK0060","BK0096","BK1593","02196","BK0175","BK0187","BK0188","BK0239","600196","BK0012","BK0183","BK0196"],"gpt_icon":0}],"pageSize":16,"totalPage":1,"pageCount":1,"totalSize":13}]}}